Latest in Merck's
Sort by
3 items
-
Merck’s struggles with HPV vaccine send stock to worst selloff in almost 17 years
Merck’s stock tumbled early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset better-than-expected fourth-quarter earnings.MarketWatch - 5h -
Merck shares plunge as company pauses Gardasil vaccine shipments in China, hurting 2025 outlook
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.CNBC - 5h -
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global uncertainties.The Wall Street Journal - Jan. 7
